Previous close | 1.9600 |
Open | 2.0000 |
Bid | 2.2100 |
Ask | 2.5000 |
Strike | 80.00 |
Expiry date | 2025-06-20 |
Day's range | 1.9600 - 2.0300 |
Contract range | N/A |
Volume | |
Open interest | 718 |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)